Related Experiment Video
Updated: Jan 18, 2026
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death
Ihab Abd-Elrahman1,2, Noha Khairi1,2, Taher Nassar2
1Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel.
This study developed Doxorubicin-conjugated PLGA-OCA nanoparticles to treat Diffuse large B-cell lymphoma (DLBCL). The novel nanoparticles show enhanced anti-cancer activity and reduced toxicity in DLBCL mouse models.
Area of Science:
- Oncology
- Nanomedicine
- Immunotherapy
Background:
- Drug resistance is a significant challenge in Diffuse large B-cell lymphoma (DLBCL) treatment.
- Conventional Doxorubicin (Dox) therapy faces limitations due to systemic toxicity and efficacy.
- Novel drug delivery systems are needed to improve Doxorubicin's therapeutic index for DLBCL.
Purpose of the Study:
- To investigate the efficacy of Doxorubicin delivered via poly (lactide-co-glycolic acid) (PLGA) nanoparticles functionalized with Oleyl cysteineamide (OCA) for DLBCL treatment.
- To evaluate the anti-cancer activity and immune-modulating effects of Dox-conjugated PLGA-OCA nanoparticles (DOX-OCA).
- To assess the potential of DOX-OCA nanoparticles in reducing systemic toxicity compared to free Doxorubicin.
Main Methods:
- Synthesis and characterization of PLGA nanoparticles functionalized with OCA.
- Conjugation of Doxorubicin to PLGA-OCA nanoparticles to form DOX-OCA.
- In vitro evaluation of cytotoxicity and apoptosis induction in DLBCL cell lines.
- In vivo studies in DLBCL mouse models to assess anti-tumor efficacy, immune response, and systemic toxicity.
Main Results:
- PLGA-OCA nanoparticles demonstrated enhanced immune responses and tumor cell death compared to plain PLGA nanoparticles.
- DOX-OCA nanoparticles exhibited significant in vitro and in vivo anti-cancer activity against DLBCL.
- DOX-OCA treatment resulted in remarkable anti-tumor effects with reduced systemic toxicity in DLBCL mouse models.
- Significant apoptotic cell death and induced immune responses were observed in DLBCL mouse models treated with DOX-OCA.
Conclusions:
- PLGA-OCA nanoparticles represent a promising drug delivery platform for enhancing Doxorubicin's efficacy in DLBCL.
- The developed DOX-OCA nanoparticles offer a potential therapeutic strategy for DLBCL with improved anti-tumor effects and reduced toxicity.
- This innovative delivery system holds potential for advancing cancer therapy by enhancing immune responses and mitigating side effects.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11:52Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013